Integrated information across different molecular platforms (mRNA and protein expression, DNA methylation, microRNA and whole exome sequencing, SNP arrays) identifies four main breast cancer classes [namely luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched and basal-like subtypes], differing in terms of prognosis and response to therapy [3, 4]. This evidence concerns the gene ERBB2 and breast carcinoma.